OptiNose, Inc. (NASDAQ:OPTN - Get Free Report) CEO Ramy A. Mahmoud sold 6,376 shares of the stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $5.29, for a total transaction of $33,729.04. Following the transaction, the chief executive officer now directly owns 126,931 shares of the company's stock, valued at $671,464.99. This trade represents a 4.78 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
OptiNose Trading Up 6.6 %
OPTN opened at $5.62 on Wednesday. The stock has a 50-day moving average of $5.96 and a 200 day moving average of $8.87. OptiNose, Inc. has a 12 month low of $4.82 and a 12 month high of $31.50. The firm has a market cap of $56.54 million, a P/E ratio of -1.34 and a beta of -0.17.
Wall Street Analysts Forecast Growth
A number of brokerages recently commented on OPTN. HC Wainwright increased their price target on OptiNose from $5.00 to $18.00 and gave the company a "buy" rating in a research note on Friday, January 3rd. Lake Street Capital lowered their target price on OptiNose from $45.00 to $17.00 and set a "buy" rating for the company in a research report on Thursday, January 16th. Finally, Piper Sandler cut their target price on shares of OptiNose from $45.00 to $15.00 and set an "overweight" rating for the company in a report on Wednesday, November 13th.
Get Our Latest Report on OptiNose
Hedge Funds Weigh In On OptiNose
Institutional investors and hedge funds have recently modified their holdings of the stock. Rosalind Advisors Inc. lifted its position in OptiNose by 9.8% in the third quarter. Rosalind Advisors Inc. now owns 8,287,503 shares of the company's stock worth $5,553,000 after buying an additional 740,355 shares during the last quarter. Easterly Investment Partners LLC increased its position in OptiNose by 5.0% during the third quarter. Easterly Investment Partners LLC now owns 2,359,239 shares of the company's stock valued at $1,581,000 after acquiring an additional 113,015 shares during the last quarter. GSA Capital Partners LLP purchased a new stake in shares of OptiNose in the third quarter valued at $61,000. Massachusetts Financial Services Co. MA lifted its holdings in shares of OptiNose by 5.3% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,075,638 shares of the company's stock worth $2,061,000 after acquiring an additional 155,329 shares during the last quarter. Finally, FMR LLC boosted its stake in shares of OptiNose by 3.2% during the 3rd quarter. FMR LLC now owns 16,541,849 shares of the company's stock worth $11,083,000 after purchasing an additional 518,610 shares during the period. Hedge funds and other institutional investors own 85.60% of the company's stock.
OptiNose Company Profile
(
Get Free Report)
OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
